# \#reporting

**URL:** https://discourse.datamethods.org/tag/reporting/83.md

[Latest](https://discourse.datamethods.org/latest.md) · [Categories](https://discourse.datamethods.org/categories.md) · [Tags](https://discourse.datamethods.org/tags.md)

---

## [Bayesian vs. Frequentist Statements About Treatment Efficacy](https://discourse.datamethods.org/t/bayesian-vs-frequentist-statements-about-treatment-efficacy/5945)

<div class="topic-metadata">

**Author:** [@f2harrell](https://discourse.datamethods.org/u/f2harrell)\
**Replies:** 5\
**Last updated:** [June 10, 2024, 3:34pm UTC](https://discourse.datamethods.org/t/bayesian-vs-frequentist-statements-about-treatment-efficacy/5945 "2024-06-10T15:34:52Z")

</div>

This is a place for discussing Bayesian vs. Frequentist Statements About Treatment Efficacy. Archive These comments were made using disqus on an old blog platform. Most of them were made between 2017 and 2021. Ahmed:…

---

## [Reporting Generalized Wilcoxon for Survival Analysis](https://discourse.datamethods.org/t/reporting-generalized-wilcoxon-for-survival-analysis/3956)

<div class="topic-metadata">

**Author:** [@Eslam\_Maher](https://discourse.datamethods.org/u/Eslam_Maher)\
**Replies:** 6\
**Last updated:** [March 9, 2021, 3:03pm UTC](https://discourse.datamethods.org/t/reporting-generalized-wilcoxon-for-survival-analysis/3956 "2021-03-09T15:03:17Z")

</div>

Hello, I was retrospectively comparing those who received treatment (radiotherapy) and those who did not in a cohort of patients, with regards to their time-to-death outcome. This disease is characterized by a high even…

---

## ["Observed Power" and other "Power" Issues](https://discourse.datamethods.org/t/observed-power-and-other-power-issues/731)

<div class="topic-metadata">

**Author:** [@ADAlthousePhD](https://discourse.datamethods.org/u/ADAlthousePhD)\
**Replies:** 74\
**Last updated:** [September 6, 2020, 9:26pm UTC](https://discourse.datamethods.org/t/observed-power-and-other-power-issues/731 "2020-09-06T21:26:20Z")

</div>

@zad, I saw this comment of yours on Andrew Gelman’s website and wondered if you would be willing to discuss here: “I submitted something similar to JAMA last month regarding a trial that investigated the effects of an …

---

## [Frequentist or Bayesian for Large Data](https://discourse.datamethods.org/t/frequentist-or-bayesian-for-large-data/3080)

<div class="topic-metadata">

**Author:** [@Hanis\_Kadir](https://discourse.datamethods.org/u/Hanis_Kadir)\
**Replies:** 4\
**Last updated:** [March 10, 2020, 2:38pm UTC](https://discourse.datamethods.org/t/frequentist-or-bayesian-for-large-data/3080 "2020-03-10T14:38:09Z")

</div>

I would like to do a cross-sectional study, 1-year period prevalence) and have performed the univariate analysis for my variables (i.e. frequentist t-test (no assumption for equality of variance) and chi-square (no corre…

---

## [Updates to NEJM Statistical Guidelines for Authors](https://discourse.datamethods.org/t/updates-to-nejm-statistical-guidelines-for-authors/1888)

<div class="topic-metadata">

**Author:** [@f2harrell](https://discourse.datamethods.org/u/f2harrell)\
**Replies:** 20\
**Last updated:** [August 11, 2019, 1:03pm UTC](https://discourse.datamethods.org/t/updates-to-nejm-statistical-guidelines-for-authors/1888 "2019-08-11T13:03:54Z")

</div>

The highly revered statistical consultants to the New England Journal of Medicine in conjunction with senior medical leaders have revised guidelines for statistical reporting in the journal. The new guidelines may be se…

---

## [GRADE guidelines and effect estimate & CIs](https://discourse.datamethods.org/t/grade-guidelines-and-effect-estimate-cis/1283)

<div class="topic-metadata">

**Author:** [@aleksi](https://discourse.datamethods.org/u/aleksi)\
**Replies:** 19\
**Last updated:** [July 10, 2019, 11:19am UTC](https://discourse.datamethods.org/t/grade-guidelines-and-effect-estimate-cis/1283 "2019-07-10T11:19:44Z")

</div>

The GRADE approach (Grading of Recommendations Assessment, Development and Evaluation) is very widely used tool to evaluate the certainty of evidence in healthcare. The GRADE approach is usually associated to meta-analy…

---

## [Rebranding of "Statistics" as "Machine Learning" to Sound More Impactful & Negative Fallout](https://discourse.datamethods.org/t/rebranding-of-statistics-as-machine-learning-to-sound-more-impactful-negative-fallout/1174)

<div class="topic-metadata">

**Author:** [@ADAlthousePhD](https://discourse.datamethods.org/u/ADAlthousePhD)\
**Replies:** 27\
**Last updated:** [May 11, 2019, 11:58am UTC](https://discourse.datamethods.org/t/rebranding-of-statistics-as-machine-learning-to-sound-more-impactful-negative-fallout/1174 "2019-05-11T11:58:10Z")

</div>

This article recently came to my attention: It is my opinion that calling this a “Machine Learning” approach is yet another example of stretching the term in a naked effort to make a paper seem more sophisticated. Th…

---

## [Should we ignore covariate imbalance and stop presenting a stratified 'table one' for randomized trials?](https://discourse.datamethods.org/t/should-we-ignore-covariate-imbalance-and-stop-presenting-a-stratified-table-one-for-randomized-trials/547)

<div class="topic-metadata">

**Author:** [@biostatmatt](https://discourse.datamethods.org/u/biostatmatt)\
**Replies:** 41\
**Last updated:** [December 5, 2018, 2:14pm UTC](https://discourse.datamethods.org/t/should-we-ignore-covariate-imbalance-and-stop-presenting-a-stratified-table-one-for-randomized-trials/547 "2018-12-05T14:14:59Z")

</div>

Suppose that the effect of an intervention versus control on an outcome (denoted ‘Y’) in a randomized trial will be assessed in an unadjusted fashion, e.g., using a t-test. We know that the operating characteristics of t…